Alterity Therapeutics (ATHE) to Post Earnings on Friday

Alterity Therapeutics (NASDAQ:ATHE) is expected to announce its Q4 2026 TU results before the market opens on Friday, August 28th. Analysts expect the company to announce earnings of ($0.1218) per share and revenue of $2.3210 million for the quarter. Individuals can check the company’s upcoming Q4 2026 TU earning summary page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 8:00 PM ET.

Alterity Therapeutics Stock Down 2.2%

ATHE stock opened at $4.47 on Wednesday. Alterity Therapeutics has a one year low of $2.66 and a one year high of $5.89. The company has a fifty day moving average price of $4.87 and a two-hundred day moving average price of $4.23.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on ATHE. Weiss Ratings restated a “sell (e+)” rating on shares of Alterity Therapeutics in a research note on Friday, July 17th. UBS Group set a $12.00 price target on shares of Alterity Therapeutics in a research note on Tuesday, August 11th. Craig Hallum set a $2.00 price objective on shares of Alterity Therapeutics in a research report on Tuesday, August 11th. JonesTrading began coverage on Alterity Therapeutics in a report on Tuesday, June 30th. They set a “buy” rating and a $16.00 price objective for the company. Finally, Zacks Research raised Alterity Therapeutics to a “hold” rating in a research report on Wednesday, June 17th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $10.00.

Institutional Inflows and Outflows

An institutional investor recently bought a new stake in Alterity Therapeutics stock. Citadel Advisors LLC purchased a new stake in Alterity Therapeutics Limited – Sponsored ADR (NASDAQ:ATHE) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 22,144 shares of the company’s stock, valued at approximately $83,000. Citadel Advisors LLC owned 0.25% of Alterity Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 2.14% of the company’s stock.

About Alterity Therapeutics

Alterity Therapeutics is a clinical-stage biotechnology company focused on the development of novel treatments for neurological and neurodegenerative disorders. The company’s research portfolio centers on small molecules designed to target underlying disease mechanisms, with an emphasis on improving synaptic function and mitigating neuroinflammation.

Among its lead assets is trofinetide (NNZ-2566), a peptide analog derived from insulin-like growth factor 1, which is being investigated for the treatment of Rett syndrome and Fragile X syndrome in ongoing clinical trials.